Theratechnologies Inc T.TH

Nash partnership deal

[jeffm34]

https://www.reuters.com/markets/europe/gsk-ties-up-with-arrowhead-develop-nash-drug-candidate-2021-11-22/

[jeffm34]

Financial Terms Under the terms of the agreement, Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine

[longterm56]

Whoa!!!  Please ... someone with a good contact at THTX ... make sure they are aware of this!!!!  $120M upfront for a drug not yet in Phase 2????   This should immediately increase THTX's market cap by > $100M .... immediately!!!     -LT

[SPCEO1]

It would be interesting to know if GSK even looked at Egrifta before deciding to move ahead with Arrowhead. That is a very sweet deal in this NASH environment and one has to think the science behind their drug is pretty impressive. To get terms that good, there must have been other Big Pharmas competing for the rights to Arrowhead's drug. Maybe one of those will see Egrifta as a fallback

[Wino115]

This looks like a high risk option bet. Never seen anything in the literature around RNA interference drugs for NASH treatment, but maybe it's the new-new thing. I see they have a slew of RNAi drugs for lots of highly specific individual genetic markers, but none are yet into Phase 3. I'm sure they have something around liver disease, but as we've all learned over time from Grinspoon